(E)-ethyl 3-(3,5-bis(trifluoromethyl)phenyl)acrylate | 937175-31-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-ethyl 3-(3,5-bis(trifluoromethyl)phenyl)acrylate
• 英文别名: 3,5-Bis(trifluoro-methyl)cinnamic ethyl ester；ethyl (E)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoate
• CAS: 937175-31-0
• 化学式: C₁₃H₁₀F₆O₂
• 分子量: 312.212
• InChiKey: HAOZCPUVSGROSH-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (E)-ethyl 3-(3,5-bis(trifluoromethyl)phenyl)acrylate 在 三丁基膦 、 二异丁基氢化铝 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 甲苯 、 苯 为溶剂， 生成 ethyl (2S)-3-[4-[(E)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoxy]phenyl]-2-ethoxypropanoate
  参考文献：
  名称：

  Design of potent PPARα agonists

  摘要：

  Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPAR alpha agonists. Optimum PPAR alpha potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPAR alpha potency of 0.002 mu M and a selectivity ratio to PPAR gamma and PPAR delta of 410 and 2000, respectively. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.015
• 作为产物：
  描述：

  间二三氟甲苯 、 丙烯酸甲酯（MA） 在 2,6-di(2-ethylhexyl)pyridine 、 氧气 、 palladium diacetate 、 乙酸酐 作用下， 90.0 ℃ 、101.33 kPa 条件下， 反应 36.25h， 以62%的产率得到(E)-ethyl 3-(3,5-bis(trifluoromethyl)phenyl)acrylate
  参考文献：
  名称：

  Zhang, Yang-Hui; Shi, Bing-Feng; Yu, Jin-Quan, Journal of the American Chemical Society, 2009, vol. 131, p. 5072 - 5074

  摘要：

  DOI：

文献信息

• Heck-Matsuda Reactions Catalyzed by a Hydroxyalkyl-Functionalized NHC and Palladium Acetate
  作者：Itziar Peñafiel、Isidro M. Pastor、Miguel Yus

  DOI：10.1002/ejoc.201200181

  日期：2012.6

  The functionalized NHC obtained from salt 2 is a good ligand for palladium in the Heck–Matsuda reaction of arenediazonium salts and different alkenes. The reaction is performed with low catalyst loading (0.5–1 mol-% of Pd) and in the absence of a base for acrylates. The protocol is also useful for the preparation of cinnamide derivatives. Compound U-77863 has been prepared successfully in good isolated

  在芳烃重氮盐和不同烯烃的 Heck-Matsuda 反应中，从盐 2 获得的官能化 NHC 是钯的良好配体。该反应在低催化剂负载量（0.5-1 mol% Pd）和丙烯酸酯碱的情况下进行。该协议也可用于肉桂酰胺衍生物的制备。化合物 U-77863 已成功制备，分离收率良好。发现环己烯是该反应的合适底物，在所研究的反应条件下得到相应的 1-芳基环己烯作为单一区域异构体。采用实验设计方法研究了反应的最佳参数。因此，使用一小组反应可以研究不同因素的趋势。该研究表明，最好的催化体系是由 Pd(OAc)2 和盐 2 以 1:2 的比例组合形成的。这种催化系统在不使用碱的情况下产生更好的结果。
• [EN] CETP INHIBITORS<br/>[FR] INHIBITEURS DE LA CETP
  申请人：MERCK & CO INC

  公开号：WO2006014413A1

  公开（公告）日：2006-02-09

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a -CH2-.

  具有I式结构的化合物，包括化合物的药学可接受盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，并用于治疗或预防动脉粥样硬化：在I式化合物中，B或R2是苯基，具有ortho芳基，杂环，苯并杂环或苯并环烷基取代基，并且5元环上的另一个位置具有芳香，杂环，环烷基，苯并杂环或苯并环烷基取代基，直接连接到环或通过-CH2-附加到环上。
• CETP inhibitors
  申请人：Ali Amjad

  公开号：US20060040999A1

  公开（公告）日：2006-02-23

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括该化合物的药学可接受的盐，是CETP抑制剂，可用于提高高密度脂蛋白胆固醇，降低低密度脂蛋白胆固醇，以及治疗或预防动脉粥样硬化：在I式化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基取代基，并且5元环上的另一个位置具有芳香，杂环，环烷基，苯并杂环或苯并环烷基取代基，直接连接到环或通过—CH2—连接到环。
• Cetp Inhibitors
  申请人：Ali Amjad

  公开号：US20080119476A1

  公开（公告）日：2008-05-22

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有公式I结构的化合物，包括化合物的药物可接受的盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，以及治疗或预防动脉粥样硬化。在公式I的化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基基团，5元环上的另一个位置具有芳基，杂环，环烷基，苯并杂环或苯并环烷基取代基，直接连接到环或通过-CH2-附加到环上。
• CETP INHIBITORS
  申请人：ALI Amjad

  公开号：US20100099716A1

  公开（公告）日：2010-04-22

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括该化合物的药物可接受的盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。在I式化合物中，B或R2是具有正交芳香族，杂环，苯并杂环或苯并环烷基取代基的苯基，而5元环上的另一个位置具有直接连接到环或通过-CH2-连接到环的芳香族，杂环，环烷基，苯并杂环或苯并环烷基取代基。